Navigation Links
Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
Date:12/14/2007


Worldwide Rights for All Potential Uses, Excluding U.S. and Japan

No Other Existing Therapeutic Treatment for Celiac Disease

BASINGSTOKE, England and PHILADELPHIA, December 14 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announces that it has acquired the worldwide rights, excluding the U.S. and Japan, to AT-1001 from Alba Therapeutics Corporation (Alba). AT-1001 is Alba's lead inhibitor of barrier dysfunction in various gastrointestinal disorders that is currently in Phase 2 development for the treatment of Celiac disease. Shire has acquired rights to all uses for AT-1001, which may also be studied for the treatment of Crohn's disease and other indications.

Matthew Emmens, Chief Executive Officer, commented: "The licensing of AT-1001 from Alba is a natural fit to our growing portfolio of gastrointestinal products. This product will be marketed to specialist physicians and we would expect to use our existing European sales force that is currently establishing relationships and expertise in the GI area through the marketing of MEZAVANT XL."

Financial terms of the license are geared to the successful development and commercialization of the product. Shire will pay Alba an upfront license fee of $25 million and further development and sales-based milestones totalling to a maximum of $300.5M should the product reach blockbuster status. Shire will also pay royalties on net sales of the product, with tiered, single or double digit royalty rates.

Alba and Shire will form a joint development committee to monitor R&D activities of AT-1001. Alba will fund all development until AT-1001 has completed Proof of Concept, which is expected to be in the first half of 2009, after which Shire and Alba will share equally development costs under a joint development plan.

About Celiac disease:

Celiac disease is a T-cell mediated auto-immune disease that occurs in genetically susceptible individuals and is characterized by small intestinal inflammation triggered by gluten. There are no currently marketed pharmaceutical products for this disorder and the current treatment for Celiac is complete elimination of gluten from the diet.

Celiac disease is largely under-diagnosed although recent advances in diagnostics have improved diagnosis dramatically. After screening, it is thought that the incidence is approximately 1% (1) in the western world.

About AT-1001:

AT1001 is a novel peptide that inhibits intestinal paracellular permeability by inhibiting stimulus-induced cytoskeletal rearrangement in epithelial cells that leads to the disassembly of tight junctions. It is currently under investigation in a multi-centre, double blind, placebo controlled Phase 2 dose ranging study to evaluate its safety, tolerability and efficacy in 140 Celiac subjects during gluten challenge.

Notes to Editors

Shire Plc

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"Safe Harbor" Statement Under The Private Securities Litigation Reform Act of 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research; product development including, but not limited to, the successful development of JUVISTA(R) (Human TGFbeta3) and GA-GCB (velaglucerase alfa); manufacturing and commercialization including, but not limited to, the launch and establishment in the market of VYVANSE(TM)(lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products including, but not limited to, the impact of those on Shire's ADHD franchise; patents including, but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval including, but not limited to, the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2006.

(1) Source: Rewers, Gastroenterology vol128, 2005


'/>"/>
SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. ATS Medical Expands Open Pivot Heart Valve Offerings
9. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
10. BioLife Solutions Expands Scientific Advisory Board
11. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... , ... Lajollacooks4u has become a rising hotspot for specialized team building events ... attractions. Fortune 500 companies, such as Illumina, Hewlett-Packard, Qualcomm and Elsevier, have traveled ... , Each event kicks off with an olive oil and salt-tasting competition. From ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... Michael Fitzmaurice recently became double board-certified in surgery and surgery of the hand ... Dr. Fitzmaurice is no stranger to going above and beyond in his pursuit ...
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading authority ... announced that Charles W. Stellar has been named by the WEDI Board of Directors ... 2016. As an executive leader with more than 35 years of experience in healthcare, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Cell therapies ... will be accelerated by research at Worcester Polytechnic Institute (WPI) that yielded a ... and tissue regeneration. , The novel method, developed by WPI faculty members Raymond ...
Breaking Biology Technology:
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
Breaking Biology News(10 mins):